Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00410371 | Study to Compare Two Formulations of Lamotrigine in Healthy Subjects | PHASE1 | COMPLETED | 96 | — | — | Dec 28, 2006 | Jan 25, 2007 | Sep 12, 2017 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| GI267119 | EXPERIMENTAL | 25 mg ODT tablet strength |
| Name | Type | Description |
|---|---|---|
| Lamotrigine | DRUG | Lamotrigine |
| GI267119 | DRUG | 25 mg ODT |
Inclusion Criteria: * Body weight \>50 kg (males) or \>45 kg (females) and BMI within the range 19 to 30 kg/m2 inclusive. Exclusion Criteria: * Female subjects of childbearing potential will not be eligible to participate if they are unwilling or unable to use an appropriate method of contracepti...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teladoc Health, Inc. | TDOC | 1 | NA | Undisclosed |
| Unity Health Toronto | UBX | 2 | NA | Undisclosed |